Skip to Content

Brimonidine / timolol ophthalmic Pregnancy and Breastfeeding Warnings

Brimonidine / timolol ophthalmic is also known as: Combigan

Brimonidine / timolol ophthalmic Pregnancy Warnings

Brimonidine-timolol ophthalmic has been assigned to pregnancy category C by the FDA. Animal studies of brimonidine have failed to reveal evidence of teratogenicity associated with oral brimonidine. Brimonidine crosses the placenta and enters the fetal circulation. Maternotoxic doses caused increased preimplantation losses, early absorptions/post-implantation losses, decreased viability, and/or postnatal growth reduction in rats and rabbits. Animal studies of timolol have failed to reveal evidence of teratogenicity at doses approximately 7000 times the systemic exposure following the maximum recommended human ophthalmic dose; while some maternotoxicity and/or fetotoxicity was observed with even higher doses. There are no controlled data in human pregnancy. Brimonidine-timolol ophthalmic is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Brimonidine / timolol ophthalmic Breastfeeding Warnings

There are no data on the excretion of brimonidine ophthalmic into human milk. Timolol is excreted into human milk following oral and ophthalmic administration. No adverse reactions in nursing infants have been reported, but close observation for bradycardia and other signs of beta-blockade in infants exposed to timolol via breast milk is recommended. Timolol is considered compatible with breast-feeding by the American Academy of Pediatrics. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Combigan (brimonidine-timolol ophthalmic)." Allergan Inc, Irvine, CA.

References for breastfeeding information

  1. "Product Information. Combigan (brimonidine-timolol ophthalmic)." Allergan Inc, Irvine, CA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.